UC San Diego Health, the region’s only academic medical center, delivers world-class care and translates groundbreaking research into promising new treatments for patients.
A novel research study by UC San Diego researchers will determine whether testing stored blood drops, recorded at birth, for 1,000 different molecules and chemicals can help predict autism risk years before symptoms would likely appear.
New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.
UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
As the opioid tramadol has grown in popularity so too have documented cases of adverse effects. In a new study, researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego show that patients who take tramadol are at greater risk for hypoglycemia, abnormally low blood sugar.
UC San Diego researchers report that climate change is a chronic mental health stressor, and promotes a variety of mental health problems. The 2018 Camp Fire is a case study.
Becker's Hospital Review, September 24
Becker's Clinical Leadership, September 28
STAT News, September 29
FOX 5/KUSI, September 30
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
